Diagnostic Performance of Transabdominal Ultrasonography for Pancreatic Fat in Adults with Metabolic Risk Factors for NAFPD: Comparison with a Study-Defined Two-Echo MRI Index

Diagnostics, 2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3390/diagnostics16182959
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background/Objectives: To evaluate an exploratory ordinal transabdominal ultrasonography score against a study-defined semiquantitative two-echo chemical-shift MRI pancreatic fat index ≥ 5%. Methods: This prospective paired diagnostic accuracy study included 150 adults aged 30–60 years with metabolic abnormalities or risk factors and technically adequate ultrasonography. A score ≥ 1 was the primary positive index-test result. Diagnostic accuracy, ROC AUC, and ordinal correspondence were evaluated. Results: After nine clinical exclusions, pancreatic ultrasonography was technically evaluable in 150 of 170 participants (88.2%; 95% CI, 82.5–92.3%). For the study-defined MRI index ≥ 5%, sensitivity was 76.8% (95% CI, 66.6–84.6%), specificity was 77.9% (95% CI, 66.7–86.2%), accuracy was 77.3% (95% CI, 70.0–83.3%), and AUC was 0.812 (95% CI, 0.748–0.876). Exact four-category agreement was 45.3%, and quadratically weighted kappa was 0.504 (95% CI, 0.387–0.612). Conclusions: These estimates describe agreement and discrimination relative to the study-defined two-echo MRI index in selected adults with metabolic risk and technically adequate ultrasonography. They should not be interpreted as diagnostic accuracy for histologically confirmed pancreatic steatosis or standardized MRI-PDFF-defined disease. The exploratory score is not a quantitative substitute for MRI and requires reproducibility assessment and external validation.